Abbott Laboratories (NYSE: ABT) reported Q3 EPS of $1.18, $0.01 better than the analyst estimate of $1.17. Revenue for the quarter came in at $9.82 billion versus the consensus estimate of $9.65 billion.

Abbott Laboratories sees FY2011 EPS of $4.64-$4.66, versus prior guidance of $4.58-$4.68 and the consensus of $4.64.

Earnings Guidance